Celgene Corporation (NASDAQ:CELG) : 14 investment research analysts covering Celgene Corporation (NASDAQ:CELG) have an average price target of $142.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $162 and the lowest target is $120 for the short term. Analysts expect the variance to be within $13.97 of the average price.
Celgene Corporation has lost 2.02% in the last five trading days and dropped 6.97% in the last 4 weeks. Celgene Corporation has dropped 2.53% during the last 3-month period . Year-to-Date the stock performance stands at -17.64%. Also, BTIG Research downgrades its view on Celgene Corporation (NASDAQ:CELG) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on June 1, 2016.
Celgene Corporation (NASDAQ:CELG) : 17 analysts are covering Celgene Corporation (NASDAQ:CELG) and their average rating on the stock is 1.41, which is read as a Strong Buy. 13 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Celgene Corporation (NASDAQ:CELG) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Celgene Corporation (NASDAQ:CELG): The stock opened at $98.81 on Thursday but the bulls could not build on the opening and the stock topped out at $98.99 for the day. The stock traded down to $97.19 during the day, due to lack of any buying support eventually closed down at $98.63 with a loss of -0.18% for the day. The stock had closed at $98.81 on the previous day. The total traded volume was 4,843,295 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged that Hugin Robert J, director officer (see remarks) of Celgene Corp /De/, had unloaded 75,000 shares at an average price of $100.16 in a transaction dated on June 20, 2016. The total value of the transaction was worth $7,512,000.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.